Roundtable Discussion: Priorities for the Cell and Gene Field
Three experts give their views on the state of play in cell and gene manufacturing, and the challenges that lie ahead
Stephanie Sutton | | Video
Cell and gene therapy is arguably one of the most exciting sectors of the drug development industry right now. In this roundtable, we invite three experts to discuss the turning points for the field so far, the manufacturing challenges, and what can be done to lower the costs of these medicines.
Komal Hatti, Director, Process Architect, IPS-Integrated Project Services
Komal has two decades of experience designing a range of building types for the pharmaceutical industry. She specializes in laboratories and research facilities, at an international scale. Her portfolio also includes pharmaceutical manufacturing, compounding pharmacies and vivariums.
Tim Lannan, Senior Director, Rare Disease New Product
Leader – Launch Excellence, Pfizer Global Supply
Tim has over 30 years’ experience in the healthcare sector and today is a Pfizer CMC expert focusing on predominantly late-stage, rare disease product development, including gene therapies, biologics, and small molecules. Throughout his career, Tim has held a variety of roles in the healthcare sector including CMC Program Leadership, Manufacturing Validation, and Process Engineering.
Alan Boyd, CEO of Boyds
Alan Boyd is globally recognized as a pioneer in gene-based therapies, having led the development of Cerepro, the first gene therapy to be submitted to the EMA for approval as a prescription medicine. Although it did not subsequently receive approval, its marketing authorization application and review by the EMA paved the way for cell and gene-based therapies that followed, setting the future standards as required by regulatory agencies worldwide. He founded Boyds in 2005 to support early-stage life science-based companies and academic groups, helping translate their research ideas into potential medicines.